PPARGC1A and melanoma: Indeed, increased MITF and PGC1α expression is found in patients with acquired resistance, but mTORC1/2 inhibition can overcome PGC1α upregulation in melanoma cells, rendering them sensitive to MEK inhibition (Gopal et al., 2014).